Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.85 |
| ▸ | HTR2C | P28335 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | CASP6 | P55212 | 1/20 | 0.84 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL1045 | 1.00 | KCNH2 (0.85) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Maleic Acid SCHEMBL1052 | 0.95 | KCNH2 (0.76) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Fumaric Acid SCHEMBL1053 | 0.95 | KCNH2 (0.76) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL29377019 | 0.92 | KCNH2 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL631 | 0.92 | KCNH2 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL806 | 0.92 | CASP6 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL29387635 | 0.92 | CASP6 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL635233 | 0.91 | KCNH2 (0.96) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL850 | 0.90 | KCNH2 (0.90) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Maleic Acid SCHEMBL871 | 0.90 | KCNH2 (0.68) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1151578-A | — | — | None | — | — | JP | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-2525830-B1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2016-05-11 | — | — | EP | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| US-5360800-A | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | GLAXO GROUP LIMITED (GB) | 1994-11-01 | — | — | US | disclosed |
| JP-H01151578-A | LACTAM DERIVATIVE | GLAXO GROUP LTD | 1989-06-14 | — | — | JP | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | HTR3A 2680/4885KCNH2 3022/4885CYP1A2 3096/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | HTR3A 2680/4885KCNH2 3022/4885CYP1A2 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.